32.60
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Wedbush Adjusts Viridian Therapeutics Price Target to $47 From $42, Maintains Outperform Rating - marketscreener.com
VRDN: Wedbush Raises Price Target to $47 While Maintaining Outpe - GuruFocus
With Viridian Therapeutics Stock Surging, Have You Considered The Downside? - Trefis
What analysts say about Viridian Therapeutics Inc stockEarnings Growth Projections & High Return Capital Gain - earlytimes.in
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 1-Year HighWhat's Next? - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 5, 2025 - BioSpace
Viridian Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Why Viridian Therapeutics Inc. (1S1) stock fits value portfolios2025 AllTime Highs & Smart Allocation Stock Tips - Newser
Viridian Therapeutics stock hits 52-week high at 32.58 USD By Investing.com - Investing.com Canada
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Sahm
Viridian Therapeutics stock hits 52-week high at 32.58 USD - Investing.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
How Viridian Therapeutics Inc. (1S1) stock gains from tech spendingMarket Sentiment Summary & Daily Chart Pattern Signal Reports - Newser
Can Viridian Therapeutics Inc. (1S1) stock retain market dominanceJuly 2025 Breakouts & Safe Entry Point Identification - Newser
How analysts revise price targets for Viridian Therapeutics Inc. (1S1) stockJuly 2025 Final Week & High Yield Stock Recommendations - Newser
Is Viridian Therapeutics Inc. (1S1) stock suitable for passive index fundsJuly 2025 Trade Ideas & Daily Technical Forecast Reports - Newser
William Blair Initiates Coverage of Viridian Therapeutics (VRDN) with Outperform Recommendation - Nasdaq
William Blair Initiates Coverage on Viridian Therapeutics (VRDN) with Outperform Rating | VRDN Stock News - GuruFocus
William Blair Initiates Viridian Therapeutics at Outperform - marketscreener.com
Why Viridian Therapeutics Inc. (1S1) stock is favored by hedge fundsTrade Exit Summary & Detailed Earnings Play Alerts - Newser
Loomis Sayles & Co. L P Sells 31,884 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Avoiding Lag: Real-Time Signals in (VRDN) Movement - news.stocktradersdaily.com
Geode Capital Management LLC Purchases 20,089 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Will Viridian Therapeutics Inc. stock attract more institutional investorsTrade Exit Summary & Real-Time Volume Analysis - BỘ NỘI VỤ
Viridian Therapeutics (VRDN): Revisiting Valuation After Analyst Upgrades and Robust Revenue Growth - Sahm
Will Viridian Therapeutics Inc. stock continue upward momentumMarket Risk Summary & Breakout Confirmation Trade Signals - BỘ NỘI VỤ
Intech Investment Management LLC Reduces Stock Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Sets New 1-Year HighShould You Buy? - MarketBeat
Truist Securities Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Truist Securities Initiates Coverage on VRDN with Buy Rating | V - GuruFocus
Truist Securities initiates coverage on Viridian Therapeutic stock with Buy rating - Investing.com Canada
Why Viridian Therapeutics Shares Are Climbing Higher - TipRanks
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 39% Price Boost Is Out Of Tune With Revenues - simplywall.st
Viridian Therapeutics Inc. (VRDN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Viridian Therapeutics stock hits 52-week high at $30.15 By Investing.com - Investing.com Nigeria
Viridian Therapeutics stock hits 52-week high at $30.15 - Investing.com India
Discipline and Rules-Based Execution in VRDN Response - news.stocktradersdaily.com
Is Viridian Therapeutics Inc. stock attractive for hedge fundsDollar Strength & Stepwise Entry and Exit Trade Signals - newser.com
Is Viridian Therapeutics Inc. stock cheap at current valuation2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com
How Viridian Therapeutics Inc. (1S1) stock compares with top peersJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
Is Viridian Therapeutics Inc. stock attractive for growth ETFsJuly 2025 WrapUp & Daily Volume Surge Trade Alerts - newser.com
Will Viridian Therapeutics Inc. stock benefit from sector rotationQuarterly Portfolio Summary & Weekly High Return Stock Opportunities - newser.com
Will Viridian Therapeutics Inc. stock remain a Wall Street favoriteMarket Rally & High Yield Equity Trading Tips - newser.com
Will Viridian Therapeutics Inc. stock keep outperforming rivals2025 Trade Ideas & High Win Rate Trade Tips - newser.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):